[{"arm_notes": "", "treatment_id": null, "treatment_name": "Drug : The investigational product for this study is CP-COV03-T (Niclosamide 50 mg; Hyundai Bioscience Co.; Ltd.) and the reference drug and CP-COV03-R (Niclosamide 50 mg placebo; Hyundai Bioscience Co.; Ltd.)The dose of test group 1 is 900mg/day. Total 9 capsules (CP-COV03-T 6 capsules + CP-COV03-R 3 capsules) are taken 3 times a day (approximately every 8 hour) for 5 days.The dose of Test Group 2 is 1350 mg/day. Total 9 capsules (CP-COV03-T 9 capsules) are taken 3 times a day (approximately every 8 hour) for 5 days.The control group takes CP-COV03-R(placebo) 9 capsules 3 times a day (approximately every 8 hour) for 5 days.Investigational product should be swallowed whole with water; and the capsules should not be chewed before swallowing.It is usually taken before breakfast; 2 hours after lunch; and 2 hours after dinner; on an empty stomach if possible.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "900mg/day", "treatment_id": 883, "treatment_name": "Niclosamide", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "1350 mg/day", "treatment_id": 883, "treatment_name": "Niclosamide", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]